Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Cholesterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 6/20 | 0.83 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.79 |
| ▸ | OSBP | P22059 | 6/20 | 0.98 |
| ▸ | RORC | P51449 | 5/20 | 0.98 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.98 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.83 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.82 |
| ▸ | CRYAB | P02511 | 1/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.79 |
| ▸ | ITGAV | P06756 | 1/20 | 0.79 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.79 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.79 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.78 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.74 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL653609 | 1.00 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27305544 | 1.00 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27675534 | 1.00 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21445079 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23365796 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23761109 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21539517 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL20607477 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22225160 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21707472 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10133093-B2 | Doping capsules, composite systems comprising these and also use thereof | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2018-11-20 | — | — | US | claimed |
| US-20160202500-A1 | DOPING CAPSULES, COMPOSITE SYSTEMS COMPRISING THESE AND ALSO USE THEREOF | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2016-07-14 | — | — | US | claimed |
| EP-2222760-B1 | Use of doping capsules for solar protection and heat reflection | FRAUNHOFER GES FORSCHUNG (DE) | 2013-04-03 | — | — | EP | claimed |
| US-20120043491-A1 | DOPING CAPSULES, COMPOSITE SYSTEMS CONTAINING SAID CAPSULES AND USE THEREOF | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2012-02-23 | — | — | US | claimed |
| WO-2008131192-A2 | CRYSTALLINE CHOLESTROL AND PREVENTION OF ATHEROSCLEROSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-10-30 | — | — | WO | claimed |
| US-20030236443-A1 | Methods and apparatus for the identification and stabilization of vulnerable plaque | CESPEDES EDUARDO IGNACIO (US) | 2003-12-25 | — | — | US | claimed |
| WO-2003088817-A2 | METHODS AND APPARATUS FOR THE IDENTIFICATION AND STABILIZATION OF VULNERABLE PLAQUE | KENNETH MICHLITSCH J (US) | 2003-10-30 | — | — | WO | claimed |
| EP-1354209-A2 | METHOD FOR IDENTIFYING COMPOUNDS TO TREAT MEDICAL PATHOLOGIES ASSOCIATED WITH MOLECULAR CRYSTALLIZATION | Shell, John W. (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020132758-A1 | Method for identifying compounds to treat medical pathologies associated with molecular crystallization | SHELL JOHN W (US) | 2002-09-19 | — | — | US | claimed |
| WO-2002057796-A2 | COMPOUNDS FOR TREATING PATHOLOGIES ASSOCIATED WITH MOLECULAR CRYSTALLIZATION | SHELL JOHN W (US) | 2002-07-25 | — | — | WO | claimed |
| US-5858398-A | MICROPARTICLES CONTAINING ACTIVE AGENT, MIXTURE OF PHOSPHOLIPIDS, MIXTURE OF NONIONIC SURFACTANTS, STEROL SUSPENDED IN FATTY ACID | ISOMED INC. (US) | 1999-01-12 | — | — | US | claimed |
| EP-0726761-A1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOTECH MEDICAL, INC. (US) | 1996-08-21 | — | — | EP | claimed |
| WO-1995012385-A1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOTECH MEDICAL, INC. (US) | 1995-05-11 | — | — | WO | claimed |
| CN-119970691-A | Application of resveratrol in preparing medicament for preventing or treating gall-stone | 安徽理工大学 | 2025-05-13 | — | — | CN | disclosed |
| US-20250058027-A1 | Nanoyarns as Drug-Releasing Facilitator | AMRITA VISHWA VIDYAPEETHAM (IN) | 2025-02-20 | — | — | US | disclosed |
| US-11779546-B2 | Disassembly of cholesterol crystals | IP SCIENCE LIMITED (GB) | 2023-10-10 | — | — | US | disclosed |
| US-4917898-A | Pharmaceutical compositions for the prophylaxis and therapy of calculosis of biliary tract and of biliary dyspepsia | Pharmaricherche Di Allesandra Tonozzi e C. s.a.s. (IT) | 1990-04-17 | — | — | US | disclosed |
| US-4826679-A | Composition and methods for alleviating cystic fibrosis | UNIVERSITE DE MONTREAL (CA) | 1989-05-02 | — | — | US | disclosed |
| EP-0293751-A2 | Taurohyodeoxycholic acid for the therapy of calculosis of the biliary tract and of biliary dyspepsia | ENOSYS S.A. (CH) | 1988-12-07 | — | — | EP | disclosed |
| US-4206132-A | Lanthanide chelate of a fluorinated ligand | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779546-B2 | Disassembly of cholesterol crystals | NPC1L1, CETP, NPC1 | GRIN2A 4320/4885ITGB3 3830/4885OSBP 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.